Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T for R/R Non-Hodgkin Lymphoma
NCT04626739Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Apr 2020
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SENL-B19, anti-CD22 chimeric antigen receptor T cells and SL19+22 CAR-T in non-Hodgkin lymphoma (NHL), sponsored by Senlang Bio. Primary endpoints: Number of Participants with Severe/Adverse Events at 28 days and CAR-T Cell expansion level at 24 months. Status: unknown.
02
Drugs
SENL-B19anti-CD22 chimeric antigen receptor T cellsSL19+22 CAR-T
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04626739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626739.